Skip to main content
    O

    Oragenics Inc (OGEN)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • AMEX

    $0.19
    -0.01 (-5.92%)

    Market Cap: $906,900

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Oragenics Inc (OGEN) Financials: Revenue, Profit and Cash Flow

    Updated Nov 12, 2026. Financial statements from company filings, amounts in US dollars.

    Oragenics reported revenue of $0 for the fiscal year ended Dec 31, 2025. That year, net income was -$9.84M, operating cash flow was -$9.25M and free cash flow was -$9.25M. The quarter ended Sep 30, 2026 had revenue of $0 and net income of -$2.60M.

    Revenue and Margins

    The company reported no revenue in the fiscal year ended Dec 2025, with an operating loss of $9.36M.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$0N/AN/AN/AN/A
    Dec 2024$0-100.0%N/AN/AN/A
    Dec 2023$37.65K-71.4%100.0%-55519.9%-54858.1%
    Dec 2022$131.52K+51.2%100.0%-10964.6%-10864.0%
    Dec 2021$86.99KN/A100.0%-18130.3%-18062.0%
    Dec 2020$0N/AN/AN/AN/A
    Dec 2019$0N/AN/AN/AN/A
    Dec 2018$0N/AN/AN/AN/A
    Dec 2017$0N/AN/AN/AN/A
    Dec 2016$0N/AN/AN/AN/A
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Sep 2026, the net loss narrowed from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$0$0$37.65K$131.52K$86.99K$0$0$0$0$0
    Gross profit$0$0$37.65K$131.52K$86.99K$0$0$0$0$0
    Research and development$2.39M$4.11M$15.49M$10.07M$10.59M$22.11M$12.12M$5.97M$3.54M$4.75M
    Operating income-$9.36M-$10.56M-$20.90M-$14.42M-$15.77M-$26.64M-$15.88M-$9.99M-$6.72M-$8.54M
    Net income-$9.84M-$10.57M-$20.66M-$14.29M-$15.71M-$26.43M-$15.57M-$9.91M-$6.73M-$7.01M
    EBITDA-$8.60MN/A-$20.81M-$14.36M-$15.73M-$26.59M-$15.82M-$9.96M-$6.46M-$8.46M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$0$0$0$0$0$0$0$3.14M$0$0$0-$37.65K
    Gross profit$0$0$0N/A$0$0$0$1.57M$0$0$0-$11.04M
    Operating income-$2.60M-$2.59M-$2.26M-$2.50M-$3.12M-$1.71M-$2.03M-$3.36M-$2.44M-$2.31M-$2.46M-$12.80M
    Net income-$2.60M-$2.53M-$2.20M-$2.29M-$3.07M-$2.27M-$2.22M-$3.35M-$2.46M-$2.31M-$2.45M-$12.75M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of $227.35K by $4.17M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$10.07M$1.47M$4.97M$14.76M$28.23M$18.68M$19.75M$22.05M$7.21M$4.31M
    Current assets$10.07M$1.47M$3.87M$14.29M$27.71M$17.98M$18.84M$21.93M$7.19M$4.22M
    Cash and equivalents$4.40M$864.84K$3.48M$11.43M$27.27M$17.64M$18.27M$20.21M$6.17M$4.08M
    Total liabilities$1.79M$1.68M$1.80M$1.75M$1.74M$1.84M$2.52M$1.17M$898.52K$1.34M
    Short-term debt$227.35K$328.53K$312.70K$267.64K$303.42K$228.23K$143.86K$124.21K$80.48K$66.38K
    Shareholder equity$8.28M-$211.88K$3.17M$13.01M$26.49M$16.84M$17.23M$20.88M$6.32M$2.97M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$3.28M$5.49M$7.49M$10.07M$12.71M$2.14M$3.87M$1.47M$5.20M$2.71M$3.53M$4.97M
    Total liabilities$2.19M$1.82M$1.31M$1.79M$2.87M$4.27M$3.73M$1.68M$2.13M$1.38M$908.69K$1.80M
    Cash and equivalents$2.23M$3.86M$6.11M$4.40M$11.40M$1.97M$3.42M$864.84K$3.14M$1.35M$2.07M$3.48M
    Shareholder equity$1.09M$3.67M$6.18M$8.28M$9.83M-$2.13M$137.69K-$211.88K$3.08M$1.33M$2.63M$3.17M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow-$9.25M-$8.60M-$7.29M-$15.23M-$13.47M-$16.95M-$13.01M-$9.08M-$6.36M-$7.08M
    Capital expenditures$3$0$1.00M$127.52K$43.88K$0$25.21K$124.73K$124.73K$27.18K
    Free cash flow-$9.25M-$8.60M-$8.29M-$15.36M-$13.51M-$16.95M-$13.04M-$9.20M-$6.49M-$7.10M
    Dividends paidN/AN/AN/A$1.12M$1.12M$661.46K$413.21K$58.67K$0$0
    Investing cash flow$0$0-$936.28K-$115.52K-$43.88K$0-$25.21K-$124.73K$0$1.68M
    Financing cash flow$16.78M$5.98M$283.88K-$494.92K$23.14M$16.32M$11.10M$23.25M$8.45M$4.45M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$2.03M-$2.19M-$2.20M-$2.84M-$2.98M-$1.31M-$2.11M-$2.02M-$1.97M-$1.54M-$3.06M-$1.10M
    Capital expendituresN/AN/A$4$2$5$0$0$3$1$1$1$5
    Free cash flowN/AN/A-$2.20M-$2.84M-$2.98M-$1.31M-$2.11M-$2.02M-$1.97M-$1.54M-$3.06M-$1.10M
    Last 12 quarters

    Frequently Asked Questions About OGEN

    What is Oragenics' annual revenue?

    Oragenics reported revenue of $0 for the fiscal year ended Dec 31, 2025.

    Is Oragenics profitable?

    No. Oragenics reported net income of -$9.84M for the fiscal year ended Dec 31, 2025.

    How much free cash flow does OGEN generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$9.25M minus capital expenditures of $3 produced free cash flow of -$9.25M.

    How much debt does Oragenics have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $227.35K and cash and equivalents of $4.40M.